Where does Sync-rx Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Sync-rx Ltd. ranks #8,484 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Sync-rx Ltd. hold?

Sync-rx Ltd. holds 38 US utility patents granted between 2015 and 2024, spanning 9 technology areas.

What is Sync-rx Ltd.'s Innovation Score?

Sync-rx Ltd. has an Innovation Score of 37.7 out of 100 (top 43% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Sync-rx Ltd. focus on?

Sync-rx Ltd.'s top technology area is A61B (DIAGNOSIS; SURGERY; Identification) with 35 patents, ranking #539 of 7,127 assignees active in that subclass. Grants appear in 9 CPC subclasses total.

Is Sync-rx Ltd.'s patent grant rate increasing or decreasing?

Sync-rx Ltd.'s recent grant velocity is -19% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Sync-rx Ltd.'s patents?

Sync-rx Ltd.'s patents average 19.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Sync-rx Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Sync-rx Ltd.

USPTO PatentsView assignee record - 38 granted patents across 9 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Sync-rx ranks #8,484 of 49,997 tracked US assignees by granted-patent volume, with 38 patents across 9 technology areas.

#8,484
of 49,997 US assignees by volume: Top 43%
by Innovation Score (37.7/100): 19.3
avg claims per patent: -19%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R8484 · Foreign Corporation #8,484 · 38 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

GRANTS-SMALL 38 grants
UPPER-Q #8,484/49,997
PHOTO-FINISH Sapience Therapeutics
CPC-NARROW A61B · 9 areas
INNOV-THIN 37.7/100
CLAIMS-RICH 19.3 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DOWN -19% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Sapience Therapeutics, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Sync-rx’s 37.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 12.7 pts (34%) Velocity 2.9 pts (8%) Breadth 10.6 pts (28%) Claim depth 11.6 pts (31%)

Qualcomm Incorporated · highest

85
Everlight · near

38
G1 Therapeutics · near

38
ResMed R&D Germany · near

38
Roxtec AB · near

38
Sync-rx · this assignee

38
3D Lighting… · lowest

7

What this shows Sync-rx's Innovation Score is 37.7/100 (top 43% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Sync-rx?

Each dot is one of Sync-rx’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Sync-rx’s own 19.3 claims/patent is ABOVE the 17.2 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Sync-rx vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Sync-rx's grants concentrate

Sync-rx Ltd. is a focused PatentsView assignee: 9 CPC subclasses with 92.1% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2021 (9 grants) versus a trough of 2 in 2017. By volume, Sync-rx sits between SDCmaterials, Inc. and Silicon Integrated Systems Corp..

Sync-rx's three-year grant acceleration

Sync-rx Ltd. shows 6 grants in 2022–2024 against only 14 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Sdcmaterials

38
SDL

38
Shenzhen Hithium…

38
Suzhou Institute…

38
Sapience Therapeu…

38
Sarcos

38
Secureauth

38
Silicon Integrate…

38
Sync-rx ◀

38

What this shows Sync-rx holds 38 patents at rank #8,477, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Sync-rx

By rank, the assignees closest to #8,477 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Sync-rx's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Sync-rx, neither rank-band nor same-CPC leaders (those blocks stay above). In A61B (Diagnosis), Sync-rx ranks #539 of 7,127 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (38 here).

Everlight Electronics Co., Ltd. 38 Roxtec AB 38 G1 Therapeutics, Inc. 38 ResMed R&D Germany GmbH 38

Sync-rx's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

38 Top 43% higher than 57% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Sync-rx Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	8	21.1%
2016	3	7.9%
2017	2	5.3%
2018	5	13.2%
2019	3	7.9%
2020	2	5.3%
2021	9	23.7%
2023	2	5.3%
2024	4	10.5%

Which technologies does Sync-rx Ltd. patent most?

A61B - DIAGNOSIS; SURGERY; Identification 35

G06T - Image Data Processing OR Generation, IN General 31

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 22

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 17

G06V - Image OR Video Recognition OR Understanding 14

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 9

G06N - Computing Arrangements Based ON Specific Computational Models 3

G06F - Electric Digital Data Processing 1

G09G - Arrangements OR Circuits FOR Control OF Indicating Devices Using Static Means TO Present Variable Information 1

Top 9 of 9 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Sync-rx Ltd.'s patent record in context - here's where to go next.

Sync-rx Ltd.'s lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 92.1% of its portfolio - see every assignee active in that class. Explore A61B
Ranked #8,484 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Sync-rx Ltd. against SDCmaterials, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 37.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.